Last updated: February 23, 2026
What is the drug associated with NDC 67877-0678?
NDC 67877-0678 corresponds to Oxycodone Hydrochloride Extended-Release (XR). This medication is a Schedule II opioid pain reliever used for managing moderate to severe chronic pain when around-the-clock analgesia is required.
Market Overview
Market Size and Demand
The demand for extended-release opioids, including oxycodone XR, remains significant due to its use in managing persistent pain conditions, especially in oncology, palliative care, and chronic pain management.
- Global Pain Management Market (2022): Valued at approximately $84 billion, with opioids constituting about 25% of this segment.
- US Opioid Market (2022): Estimated at $11 billion, with oxycodone products generating roughly $3.8 billion.
- Market Growth: Expected to grow at a compound annual growth rate (CAGR) of around 3% through 2027, driven by aging populations and increased chronic pain prevalence.
Competitive Landscape
Key marketed products for extended-release oxycodone include:
- Purdue Pharma's OxyContin
- Mallinckrodt's Oxaydo
- Teva's Oxycodone ER (generic)
- Sun Pharma's Oxycodone ER (generic)
These products dominate the market, with generic versions accounting for a large share due to cost competitiveness. Brand-name drugs hold premium pricing positions, typically 15-25% higher than generics.
Regulatory Environment
The U.S. Food and Drug Administration (FDA) tightly regulates opioids, influencing market entry and pricing. Recent moves to curb opioid misuse have increased restrictions on prescribing and distribution, impacting revenue streams.
Price Trends and Projections
Current Pricing
- Brand-name OxyContin (Extended-Release): Wholesale acquisition cost (WAC): approximately $250–$350 per 60-count, 10 mg tablets.
- Generic Oxycodone ER: WAC ranges from $80–$150 per 60-count, 10 mg tablets.
Factors Influencing Price Changes
- Regulatory pressures leading to market exit of some producers.
- Patent expirations releasing generics, reducing prices.
- Supply chain issues causing temporary price increases.
Projected Price Trends (2023–2027)
| Year |
Generic Price Range (per 60 tablets, 10 mg) |
Brand Name Price Range (per 60 tablets, 10 mg) |
| 2023 |
$70–$150 |
$250–$350 |
| 2024 |
$65–$140 |
$230–$330 |
| 2025 |
$60–$130 |
$210–$310 |
| 2026 |
$55–$120 |
$200–$290 |
| 2027 |
$50–$110 |
$190–$280 |
Expected decrease in generic prices is driven by increased competition, with generics expected to settle around $50–$70 per 60 tablets by 2027. Brand-name prices are projected to decline slightly due to patent expiration and competitive pressure.
Factors Affecting Price Projections
- Patent expirations for key formulations are anticipated around 2025–2026, likely reducing brand-name prices.
- Regulatory restrictions and efforts to limit opioid misuse could decrease prescriptions, impacting revenue.
- Potential biosimilar or alternative therapies may influence market share, further pressuring prices.
Market Risks and Opportunities
Risks
- Regulatory crackdowns reducing prescribing and reimbursement rates.
- Litigation risks associated with opioid epidemic lawsuits.
- Shift to non-opioid analgesics reducing demand.
Opportunities
- Development of abuse-deterrent formulations (ADFs):potential premium pricing.
- Expansion in international markets: some countries have less restrictive regulations.
- Innovative delivery systems: implants or smart drug delivery devices may command higher prices.
Summary
The market for extended-release oxycodone, including NDC 67877-0678, remains sizable but faces regulatory and competitive pressures. Price trends show a decline driven largely by generic competition, with future valuations depending on patent status, regulatory environment, and potential innovations.
Key Takeaways
- The current market for oxycodone XR products is approximately $3.8 billion in the U.S., with steady growth expected.
- Generic prices are projected to decline to roughly $50–$70 per 60 tablets by 2027.
- Patent expirations and regulatory changes will largely influence future pricing and market dynamics.
- Abuse deterrent formulations and international expansion represent key growth opportunities.
- Legal and regulatory risks pose notable threats to market stability.
FAQs
1. What factors most influence oxycodone XR pricing over the next five years?
Patent expirations, regulatory restrictions, competition from generics, and formulation innovations.
2. How could regulatory changes affect the oxycodone market?
Restrictions on prescribing, increased misuse mitigation measures, and potential rescheduling could reduce demand and prices.
3. Are there significant differences in pricing between brand-name and generic oxycodone XR?
Yes. Brand names typically command 15-25% higher prices; generics are priced lower due to competition.
4. How might the market for NDC 67877-0678 evolve internationally?
Less restrictive pharmaceutical regulations in some countries could increase demand and stable pricing outside the U.S.
5. What technological developments could impact future pricing?
Abuse-deterrent formulations, advanced delivery systems, and biosimilars may alter market valuation and profitability.
References
[1] IBISWorld. (2022). Pain Management Market Size Report.
[2] IQVIA. (2022). US Prescription Drug Market Data.
[3] FDA. (2022). Opioid Prescribing and Manufacturing Regulations.
[4] Statista. (2022). Global Pain Management Market Forecast.
[5] FDA. (2022). Opioid Abuse-Deterrent Formulations and Regulations.
